ESSA Pharma Stock (NASDAQ:EPIX)

Forecast Ownership Financials Chart

Previous Close

$1.72

52W Range

$1.40 - $11.67

50D Avg

$5.12

200D Avg

$6.31

Market Cap

$75.87M

Avg Vol (3M)

$803.50K

Beta

1.84

Div Yield

-

EPIX Company Profile

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

50

IPO Date

Mar 13, 2015

Website

EPIX Performance

EPIX Financial Summary

	Sep 23	Sep 22	Sep 21
Revenue	-	-	-
Operating Income	$-26.58M	$-35.34M	$-36.91M
Net Income	$-26.58M	$-35.10M	$-36.81M
EBITDA	$-26.46M	$-35.22M	$-36.80M
Basic EPS	$-0.60	$-0.80	$-0.96
Diluted EPS	$-0.60	$-0.80	$-0.96

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 08Sep 23, 08 | 11:58 PM

Q4 07Feb 25, 08 | 6:57 PM

Peer Comparison

Ticker	Company
SPRO	Spero Therapeutics, Inc.
SMMT	Summit Therapeutics Inc.
CYTO	Altamira Therapeutics Ltd.
ATXI	Avenue Therapeutics, Inc.
AGLE	Spyre Therapeutics, Inc.